PharmaMedDevice Industry Blog

Calling all Regulatory Affairs Professionals!

As you know, the role of today’s regulatory affairs professional is changing as the life science industries continue to converge.  It is becoming increasingly more difficult to remain solely a “medical device” or “pharma” person as combination products continue to become more mainstream.  Individuals who can apply their multi-modality expertise across the life science industries are a real asset to the combination products market. According to RAPS research, the number of regulatory professionals involved in combination products has increased from an estimated 12% in 1999 to nearly 30% in 2006.

Continued Advancements for Diabetes Treatments – Intranasal Drug Delivery

Bentley Pharmaceuticals recently announced positive findings from Global Phase II Clinical related to a new intranasal insulin spray - NasulinTM.
The findings were encouraging – with the product showing results equivalent in many key measures when compared with traditional injectable insulin.  The healthcare market has made significant advancements related to improving the treatment options for the millions of Americans who treat diabetes on a daily basis.  Bentley is currently seeking collaboration partners to help conduct additional clinical studies.  This new product would not require constant refrigeration and the delivery device is small enough to discretely fit into a pocket or purse for added convenience and improved patient compliance.  For diabetic patients who suffer from COPD or asthma, the intranasal delivery route represents a new option for those who are not candidates for pulmonary delivery devices. 

Original Press Release link:  http://www.bentleypharm.com/pdfs/pressreleases/pr-062507.pdf